OUH - Oslo Myeloma Center

Oslo Myeloma Center

F. SchjesvoldGroup leader — F. Schjesvold
Group leader

Group leader: Fredrik Schjesvold, MD, PhD

About our research:

Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordics.

Since 2015, 982 patients have been enrolled in 64 clinical studies in patients with smoldering multiple myeloma and multiple myeloma including newly diagnosed and relapsed/refractory patients in phase 1, 2, 3 and 4 studies.

Ongoing trials

Scroll to top

Recent publications

Moore KLF, Rognvaldsson S, Szabo AG, Vaitekėnaitė V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH (2025)
Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group
Haematologica (in press)
DOI 10.3324/haematol.2025.287344, PubMed 40905090

Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J et al. (2025)
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
J Clin Oncol, JCO2501767 (in press)
DOI 10.1200/JCO-25-01767, PubMed 40779730

Våtsveen TK, Giliberto M, Bjornsdottir V, Centonze F, Besse A, Frey Y, Skånland SS, Tveita A, Alirezaylavasani A, Imbery JF, Misund K, Reiterer V, Zahoor M, Driessen C, Besse L, Tasken K, Schjesvold FH, Farhan H, Munthe LA (2025)
Targeting proteostasis in multiple myeloma through inhibition of LTK
Leukemia, 39 (9), 2237-2245
DOI 10.1038/s41375-025-02682-8, PubMed 40634511

More publications